Stopping Tumor Necrosis Factor Inhibitor Treatment in Patients With Established Rheumatoid Arthritis in Remission or With Stable Low Disease Activity: A Pragmatic Multicenter, Open-Label Randomized Controlled Trial

Full dose, reduced dose or discontinuation of etanercept in rheumatoid arthritis

(2015) Ronald F van Vollenhoven et al.   ANNALS OF THE RHEUMATIC DISEASES

Disease activity guided dose reduction and withdrawal of adalimumab or etanercept compared with usual care in rheumatoid arthritis: open label, randomised controlled, non-inferiority trial

(2015) N. van Herwaarden et al.   BMJ-British Medical Journal

Disease activity guided dose reduction and withdrawal of adalimumab or etanercept compared with usual care in rheumatoid arthritis: open label, randomised controlled, non-inferiority trial

(2015) N. van Herwaarden et al.   BMJ-British Medical Journal

Safety of synthetic and biological DMARDs: a systematic literature review informing the 2013 update of the EULAR recommendations for management of rheumatoid arthritis

(2014) Sofia Ramiro et al.   ANNALS OF THE RHEUMATIC DISEASES

Discontinuation of tumour necrosis factor inhibitors in patients with rheumatoid arthritis in low-disease activity: persistent benefits. Data from the Corrona registry

(2014) Arthur Kavanaugh et al.   ANNALS OF THE RHEUMATIC DISEASES

Discontinuation of adalimumab treatment in rheumatoid arthritis patients after achieving low disease activity

(2014) Masayoshi Harigai et al.   Modern Rheumatology

Discontinuation of adalimumab after achieving remission in patients with established rheumatoid arthritis: 1-year outcome of the HONOR study

(2013) Yoshiya Tanaka et al.   ANNALS OF THE RHEUMATIC DISEASES

EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2013 update

(2013) Josef S Smolen et al.   ANNALS OF THE RHEUMATIC DISEASES

Maintenance, reduction, or withdrawal of etanercept after treatment with etanercept and methotrexate in patients with moderate rheumatoid arthritis (PRESERVE): a randomised controlled trial

(2013) Josef S Smolen et al.   LANCET

Rheumatoid arthritis, anti-tumour necrosis factor therapy, and risk of malignant melanoma: nationwide population based prospective cohort study from Sweden

(2013) P. Raaschou et al.   BMJ-British Medical Journal

Incidences of overall and site specific cancers in TNFα inhibitor treated patients with rheumatoid arthritis and other arthritides – a follow-up study from the DANBIO Registry

(2012) Lene Dreyer et al.   ANNALS OF THE RHEUMATIC DISEASES

Construct and criterion validity of several proposed DAS28-based rheumatoid arthritis flare criteria: an OMERACT cohort validation study

(2012) Aatke van der Maas et al.   ANNALS OF THE RHEUMATIC DISEASES

2012 Update of the 2008 American College of Rheumatology recommendations for the use of disease-modifying antirheumatic drugs and biologic agents in the treatment of rheumatoid arthritis

(2012) Jasvinder A. Singh et al.   ARTHRITIS CARE & RESEARCH

Discontinuation of infliximab and potential predictors of persistent low disease activity in patients with early rheumatoid arthritis and disease activity score-steered therapy: subanalysis of the BeSt study

(2011) M. van den Broek et al.   ANNALS OF THE RHEUMATIC DISEASES

Patients with RA in remission on TNF blockers: when and in whom can TNF blocker therapy be stopped?

(2010) B. Saleem et al.   ANNALS OF THE RHEUMATIC DISEASES

Discontinuation of infliximab after attaining low disease activity in patients with rheumatoid arthritis: RRR (remission induction by Remicade in RA) study

(2010) Y. Tanaka et al.   ANNALS OF THE RHEUMATIC DISEASES

Effect of discontinuing TNFα antagonist therapy in patients with remission of rheumatoid arthritis

(2009) Olivier Brocq et al.   JOINT BONE SPINE

Contemporary treatment principles for early rheumatoid arthritis: a consensus statement

(2009) P. D. W. Kiely et al.   RHEUMATOLOGY